Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT00076999
First received: February 9, 2004
Last updated: April 25, 2014
Last verified: April 2014

February 9, 2004
April 25, 2014
November 2003
June 2010   (final data collection date for primary outcome measure)
  • Number of Severe (DAIDS Grades 3 or 4) Adverse Events Related to Drug for Treated Patients by Age Group and Formulation [ Time Frame: up to 288 weeks ] [ Designated as safety issue: No ]
    Intensity of adverse events were graded by the investigator based on the DAIDS standardized table (Division of AIDS, National Institute of Health). DAIDS Grade 3 (Severe) and Grade 4 (Life Threatening) were identified.
  • Number of Patients With Severe (DAIDS Grades 3 or 4) Laboratory Abnormalities by Age Group and Formulation [ Time Frame: up to 288 weeks ] [ Designated as safety issue: No ]
    Intensity of adverse events were graded by the investigator based on the DAIDS standardized table (Division of AIDS, National Institute of Health). DAIDS Grade 3 (Severe) and Grade 4 (Life Threatening) were identified.
Not Provided
Complete list of historical versions of study NCT00076999 on ClinicalTrials.gov Archive Site
  • Number Patients With at Least 1 log10 Viral Load Reduction From Baseline at Week 24 (Non-completers Considered Failures) [ Time Frame: baseline, week 24 ] [ Designated as safety issue: No ]
  • Number Patients With at Least 1 log10 Viral Load Reduction From Baseline at Week 48 (Non-completers Considered Failures) [ Time Frame: baseline, week 48 ] [ Designated as safety issue: No ]
  • Number Patients With at Least 1 log10 Viral Load Reduction From Baseline at Week 100 (Non-completers Considered Failures) [ Time Frame: baseline, week 100 ] [ Designated as safety issue: No ]
  • Number Patients With HIV RNA <400 Copies/mL at Week 24 (Non-completers Considered Failures) [ Time Frame: baseline, week 24 ] [ Designated as safety issue: No ]
  • Number Patients With HIV RNA <400 Copies/mL at Week 48 (Non-completers Considered Failures) [ Time Frame: baseline, week 48 ] [ Designated as safety issue: No ]
  • Number Patients With HIV RNA <400 Copies/mL at Week 100 (Non-completers Considered Failures) [ Time Frame: baseline, week 100 ] [ Designated as safety issue: No ]
  • Number Patients With HIV RNA <50 Copies/mL at Week 24 (Non-completers Considered Failures) [ Time Frame: baseline, week 24 ] [ Designated as safety issue: No ]
  • Number Patients With HIV RNA <50 Copies/mL at Week 48 (Non-completers Considered Failures) [ Time Frame: baseline, week 48 ] [ Designated as safety issue: No ]
  • Number Patients With HIV RNA <50 Copies/mL at Week 100 (Non-completers Considered Failures) [ Time Frame: baseline, week 100 ] [ Designated as safety issue: No ]
  • Baseline Median Viral Load log10 Copies/mL [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Median Change From Baseline in Viral Load log10 Copies/mL at Week 24 (Last Observation Carried Forward) [ Time Frame: baseline, week 24 ] [ Designated as safety issue: No ]
  • Median Change From Baseline in Viral Load log10 Copies/mL at Week 48 (Last Observation Carried Forward) [ Time Frame: baseline, week 48 ] [ Designated as safety issue: No ]
  • Median Change From Baseline in Viral Load log10 Copies/mL at Week 100 (Last Observation Carried Forward) [ Time Frame: baseline, week 100 ] [ Designated as safety issue: No ]
  • Baseline Median CD4+ Cell Count (Cells/mm3) [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Median Change From Baseline in CD4+ Cell Count (Cells/mm3) at Week 24 (Last Observation Carried Forward) [ Time Frame: baseline, week 24 ] [ Designated as safety issue: No ]
  • Median Change From Baseline in CD4+ Cell Count (Cells/mm3) at Week 48 (Last Observation Carried Forward) [ Time Frame: baseline, week 48 ] [ Designated as safety issue: No ]
  • Median Change From Baseline in CD4+ Cell Count (Cells/mm3) at Week 100 (Last Observation Carried Forward) [ Time Frame: baseline, week 100 ] [ Designated as safety issue: No ]
  • Median Baseline CD4 Percent [ Time Frame: baseline ] [ Designated as safety issue: No ]
    Percentage of lymphocytes that are CD4 cells
  • Median Change From Baseline in CD4 Percent at Week 24 (Last Observation Carried Forward) [ Time Frame: baseline, week 24 ] [ Designated as safety issue: No ]
    Percentage of lymphocytes that are CD4 cells
  • Median Change From Baseline in CD4 Percent at Week 48 (Last Observation Carried Forward) [ Time Frame: baseline, week 48 ] [ Designated as safety issue: No ]
    Percentage of lymphocytes that are CD4 cells
  • Median Change From Baseline in CD4 Percent at Week 100 (Last Observation Carried Forward) [ Time Frame: baseline, week 100 ] [ Designated as safety issue: No ]
    Percentage of lymphocytes that are CD4 cells
  • Number Patients With Compliance With Tipranavir Treatment Between 95 and 120 Percent at Week 8 [ Time Frame: week 8 ] [ Designated as safety issue: No ]
  • Number Patients With Compliance With Tipranavir Treatment Between 95 and 120 Percent at Week 16 [ Time Frame: week 16 ] [ Designated as safety issue: No ]
  • Number Patients With Compliance With Tipranavir Treatment Between 95 and 120 Percent at Week 24 [ Time Frame: week 24 ] [ Designated as safety issue: No ]
  • Number Patients With Compliance With Tipranavir Treatment Between 95 and 120 Percent at Week 48 [ Time Frame: week 48 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children
Multiple-dose, Open-label, Randomized, Safety and Pharmacokinetic Study of Tipranavir in Combination With Low-dose Ritonavir in HIV-infected Pediatric Patients

The primary objective of this study is to assess the safety and tolerability of tipranavir (TPV) oral formulation and soft gelatin capsules together with low-dose ritonavir in HIV-infected children and adolescents, to provide information concerning the pharmacokinetic characteristics of tipranavir and ritonavir in this age group, and to determine the relative bioavailability of the TPV liquid formulation and TPV capsule formulation in adolescents switching from liquid to capsule.

The secondary objective of this study is the determination of the dose of topranavir and ritonavir (TPV/r) in children and adolescents between 2 and 18 years of age required for an adult equivalent systemic exposure of TPV/r 500 mg / 200 mg.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
  • Drug: TPV oral solution
    Tipranavir oral solution
  • Drug: RTV oral solution
    Ritonavir oral solution
  • Experimental: TPV/r 290/115 mg/m^2
    TPV and RTV oral solution low dose
    Interventions:
    • Drug: TPV oral solution
    • Drug: RTV oral solution
  • Experimental: TPV/r 375/150 mg/m^2
    TPV and RTV oral solution high dose
    Interventions:
    • Drug: TPV oral solution
    • Drug: RTV oral solution
Salazar JC, Cahn P, Yogev R, Negra MD, Castelli-Gattinara G, Fortuny C, Flynn PM, Giaquinto C, Ruan PK, Smith ME, Mikl J, Jelaska A; PACTG 1051/BI Study Team. Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. AIDS. 2008 Sep 12;22(14):1789-98.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
115
Not Provided
June 2010   (final data collection date for primary outcome measure)

Inclusion criteria:

  1. Males and females between 2 and 18 years of age.
  2. A confirmed diagnosis of HIV-1 infection as defined by two positive assays from two different samples taken at least two weeks apart. The two results may be any combination of the following:

    HIV ribonucleic acid (RNA) detected by reverse transcriptase (RT)-polymerase chain reaction(PCR) or HIV proviral deoxyribonucleic acid (DNA) detected by PCR HIV culture p24 antigen detection Licensed HIV enzyme-linked immunosorbent assay (ELISA) with confirmatory Western blot

  3. Viral load > 1500 RNA copies/mL.
  4. Acceptable screening laboratory values indicative of adequate baseline organ function. Laboratory values are considered acceptable if severity is no higher than Grade 1 for all tests defined by the Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading Severity of Pediatric Adverse Experiences (> 3 months of age) with the following exceptions:

    Grade 2 gamma-glutamyl transferase Grade 2 cholesterol Grade 2 triglycerides

  5. Signed informed consent prior to study participation from the patient or a legal guardian.

    Active assent must be given by the patient if the child and/or adolescent is capable of understanding the provided study information (this applies to children with the intellectual age of 7 years or greater)

  6. In the opinion of the investigator, an ability to take medications and comply with the requirements of the protocol.

Exclusion criteria:

  1. Female patients of childbearing potential who:

    have a positive serum pregnancy test at screening are breast feeding are planning on becoming pregnant are not willing to use two methods of contraception to include at least one barrier method (e.g. latex condom plus spermicidal jelly/foam)

  2. Active hepatitis B or C disease defined as hepatitis B surface antigen (HBsAg) positivity or hepatitis C (HCV) antibody or RNA positivity with aspartate aminotransferase(AST)/ alanine aminotransferase(ALT) > Grade 2.
  3. Life expectancy < 12 months.
  4. Patients who are unwilling to abstain from ingesting contraindicated medications and substances which may significantly affect plasma levels of the study medications, notably:

    Grapefruit juice or Seville oranges Herbal preparations containing St. John's Wort or milk thistle Garlic supplements

  5. Active substance abuse.
  6. Use of investigational medications or vaccines within 28 days before study entry or during the trial. Some expanded access antiretroviral medications may be acceptable, but must be approved by sponsor.
  7. Requirement for any therapy for malignancy or immunomodulatory drug (e.g. interferon, cyclosporine, hydroxyurea, interleukin-2) within 28 days of study entry. Replacement intravenous gamma globulin treatment is acceptable.
  8. Any active opportunistic infection within 28 days before study entry or other clinically significant findings that may compromise the outcome of the study.
  9. Patients with malabsorption, severe chronic diarrhea or vomiting (more than two episodes of moderate or severe intensity, not attributed to medication therapy and lasting more than four days) within 28 days of the study.
  10. Evidence or symptoms of encephalopathy or developmental delay that would reduce compliance.
Both
2 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Brazil,   Canada,   France,   Germany,   Italy,   Mexico,   Puerto Rico,   Spain
 
NCT00076999
1182.14
Not Provided
Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP